SARS-CoV-2 Spike Antibody (AM009105)

Product Overview

• Article Name: SARS-CoV-2 Spike Antibody (AM009105)
• Biozol Catalog Number: ACM-91337
• Supplier Catalog Number: 91337
• Alternative Catalog Number: ACM-91337
• Manufacturer: Active Motif
• Category: Antikörper
• Alternative Names: sars-cov-2

Additional Information

Antibody Type:

Recombinant

Isotype:

IgG1

Purification:

Protein A Chromatography

Host:

Human

Molecular Weight:

141 kDa (full length S1 protein)

Reactivity:

Virus

Applications

Application Notes

Note: Clone AM009105, developed by Active Motif, is also referred to as Clone 105-9.
Details on the development and characterization of this clone are available here: Wan J., et. al. Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection. Cell Reports, 32: 107918, July 21, 2020.


This antibody has been tested by ELISA and is specific for SARS-CoV-2 Spike protein S1 Subunit of Receptor Binding Domain (RBD).

Immunogen

N/A

Buffer

140 mM Hepes, pH 7.5, 70 mM NaCl, 32mM NaOAc, 0.035% sodium azide, and 30% glycerol.

 

SARS-CoV-2 Spike Antibody (clone AM009105) tested by ELISA.
SARS-CoV-2 Spike RBD protein was coated onto microtiter plates at 0.5 µg/mL and then incubated with a dilution series of SARS-CoV-2 Spike Antibody (clone AM009105). Bound antibodies were detected with anti-human IgG conjugated to horseradish peroxidase (HRP) followed by incubation with HRP Substrate and then measuring the resulting absorbance at 450 nm.

Background

COVID-19, which is short for coronavirus disease 2019, is the official name of the respiratory disease caused by infection with the novel coronavirus SARS-CoV-2. The virus that causes COVID-19 was named SARS-CoV-2 because it is a coronavirus genetically similar to, yet distinct from, the virus that caused the severe acute respiratory syndrome (SARS) outbreak in 2003. Studying the details of how this virus replicates and causes the disease will allow scientists and physicians to more rapidly develop fast and accurate methods of detection as well as to deploy therapeutic and vaccine strategies.

This antibody was derived from COVID-19 patients who have cleared the virus. Patient serum IgG was sequenced and expressed as full-length IgG1 with human immunoglobulin heavy and light chains in mammalian 293 cells.